Clinical trial
An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in…
NCT00171730 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00171730 |
|---|---|
| Title | An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly |
| Official title | Extension to a Multi-Center, Randomized, Crossover, Open Label, Dose Finding Study to Compare the Safety, Efficacy, and Pharmacokinetics/Pharmacodynamics (PK/PD) Relationship of Multiple Doses of Pasireotide (SOM230) (200, 400, and 600 μg Bid) and Doses of Open Label Sandostatin® (SMS) (100 μg Tid)… |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acromegaly |
| Intervention type | Drug |
| Interventions | Pasireotide |
| Enrollment | 30 |
| Start date | Aug 24, 2004 |
| Primary completion | Dec 6, 2013 |
| Completion | Dec 6, 2013 |
| First posted | Sep 15, 2005 |
| Last update posted | Sep 5, 2021 |
| Countries | Australia, Belgium, France, Germany, Italy, Switzerland, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: